Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer
Full text links

Actions

Share

Review
.2022 Jun;141(6):1137-1157.
doi: 10.1007/s00439-021-02369-x. Epub 2021 Oct 1.

Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide

Affiliations
Review

Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide

Evangelia Eirini Tsermpini et al. Hum Genet.2022 Jun.

Abstract

Over the last few years, the field of pharmacogenomics has gained considerable momentum. The advances of new genomics and bioinformatics technologies propelled pharmacogenomics towards its implementation in the clinical setting. Since 2007, and especially the last-5 years, many studies have focused on the clinical implementation of pharmacogenomics while identifying obstacles and proposed strategies and approaches for overcoming them in the real world of primary care as well as outpatients and inpatients clinics. Here, we outline the recent pharmacogenomics clinical implementation projects and provide details of the study designs, including the most predominant and innovative, as well as clinical studies worldwide that focus on outpatients and inpatient clinics, and primary care. According to these studies, pharmacogenomics holds promise for improving patients' health in terms of efficacy and toxicity, as well as in their overall quality of life, while simultaneously can contribute to the minimization of healthcare expenditure.

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Abou Tayoun AN, Rehm HL (2020) Genetic variation in the Middle East-an opportunity to advance the human genetics field. Genome Med 12:116.https://doi.org/10.1186/s13073-020-00821-7 - DOI - PubMed - PMC
    1. Bain KT, Matos A, Knowlton CH, McGain D (2019) Genetic variants and interactions from a pharmacist-led pharmacogenomics service for PACE. Pharmacogenomics 20:709–718.https://doi.org/10.2217/pgs-2019-0047 - DOI - PubMed
    1. Bain KT, Knowlton CH, Matos A (2020) Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly. Pharmacogenomics 21:651–661.https://doi.org/10.2217/pgs-2019-0197 - DOI - PubMed
    1. Bank PCD, Swen JJ, Guchelaar H-J (2018) Implementation of pharmacogenomics in everyday clinical settings. Adv Pharmacol 83:219–246.https://doi.org/10.1016/BS.APHA.2018.04.003 - DOI - PubMed
    1. Bank PCD, Swen JJ, Schaap RD et al (2019) A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. Eur J Hum Genet 27:1532.https://doi.org/10.1038/S41431-019-0454-X - DOI - PubMed - PMC

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full text links
Springer full text link Springer
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp